JP4430009B2 - 新規な抗腫瘍化合物 - Google Patents

新規な抗腫瘍化合物 Download PDF

Info

Publication number
JP4430009B2
JP4430009B2 JP2005501483A JP2005501483A JP4430009B2 JP 4430009 B2 JP4430009 B2 JP 4430009B2 JP 2005501483 A JP2005501483 A JP 2005501483A JP 2005501483 A JP2005501483 A JP 2005501483A JP 4430009 B2 JP4430009 B2 JP 4430009B2
Authority
JP
Japan
Prior art keywords
cancer
compound according
val
kahalalides
allo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2005501483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006517195A (ja
JP2006517195A5 (enExample
Inventor
グリン・トーマス・フェアクロース
マリアーノ・エリセス
ヘリナ・ササック
パブロ・マニュエル・アヴィレス・マリン
マリア・デル・カルメン・ケヴァス・マルシャンテ
Original Assignee
ファーマ・マール・エス・アー・ウー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2002/004735 external-priority patent/WO2003033012A1/en
Priority claimed from GBGB0304367.6A external-priority patent/GB0304367D0/en
Priority claimed from GB0314725A external-priority patent/GB0314725D0/en
Application filed by ファーマ・マール・エス・アー・ウー filed Critical ファーマ・マール・エス・アー・ウー
Publication of JP2006517195A publication Critical patent/JP2006517195A/ja
Publication of JP2006517195A5 publication Critical patent/JP2006517195A5/ja
Application granted granted Critical
Publication of JP4430009B2 publication Critical patent/JP4430009B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2005501483A 2002-10-18 2003-10-20 新規な抗腫瘍化合物 Expired - Fee Related JP4430009B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2002/004735 WO2003033012A1 (en) 2001-10-19 2002-10-18 Kahalalide compounds for use in cancer therapy
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
GB0314725A GB0314725D0 (en) 2003-06-24 2003-06-24 New antitumoral compounds
PCT/US2003/033207 WO2004035613A2 (en) 2002-10-18 2003-10-20 4-methylhexanoic kahalaide f compound

Publications (3)

Publication Number Publication Date
JP2006517195A JP2006517195A (ja) 2006-07-20
JP2006517195A5 JP2006517195A5 (enExample) 2006-12-21
JP4430009B2 true JP4430009B2 (ja) 2010-03-10

Family

ID=32110555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005501483A Expired - Fee Related JP4430009B2 (ja) 2002-10-18 2003-10-20 新規な抗腫瘍化合物

Country Status (10)

Country Link
EP (1) EP1572726B1 (enExample)
JP (1) JP4430009B2 (enExample)
CN (2) CN101077885A (enExample)
BR (1) BR0315489A (enExample)
CA (1) CA2501089C (enExample)
ES (1) ES2357644T3 (enExample)
MX (1) MXPA05004133A (enExample)
NZ (1) NZ539093A (enExample)
WO (1) WO2004035613A2 (enExample)
ZA (1) ZA200502926B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
AU2008312400A1 (en) * 2007-10-19 2009-04-23 Albert Einstein College Of Medicine Of Yeshiva University Improved antitumoral treatments
DE102008005097B4 (de) * 2008-01-18 2011-04-07 Leibnitz-Institut für Meereswissenschaften Antitumoraler Cyclodepsipeptide, deren Herstellung und Verwendung
CA2717117A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
WO2009135939A2 (en) * 2008-05-09 2009-11-12 Pharma Mar, S.A. Depsipeptide for use in cancer therapy
HUE042801T2 (hu) * 2010-11-12 2019-07-29 Pharma Mar Sa Kombinációs terápia mitózisgátlóval
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
PH12022551216A1 (en) 2019-11-21 2023-07-17 Pharma Mar Sa Methods of treating small cell lung cancer with lurbinectedin formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6178719A (ja) * 1984-09-25 1986-04-22 Tanabe Seiyaku Co Ltd 総合輸液剤
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
IL155297A0 (en) * 2000-10-31 2003-11-23 Pharma Mar Sa Kahalalide f formulation
WO2003033012A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
CA2501089C (en) 2012-07-17
EP1572726B1 (en) 2010-12-08
BR0315489A (pt) 2005-08-23
JP2006517195A (ja) 2006-07-20
WO2004035613A3 (en) 2004-07-29
CN101077885A (zh) 2007-11-28
MXPA05004133A (es) 2005-10-05
CA2501089A1 (en) 2004-04-29
CN100591691C (zh) 2010-02-24
CN1705677A (zh) 2005-12-07
ES2357644T3 (es) 2011-04-28
ZA200502926B (en) 2006-02-22
NZ539093A (en) 2007-10-26
WO2004035613A2 (en) 2004-04-29
EP1572726A2 (en) 2005-09-14

Similar Documents

Publication Publication Date Title
US7683028B2 (en) Kahalalide compositions
JP5372096B2 (ja) 新規な抗腫瘍化合物
JP4430009B2 (ja) 新規な抗腫瘍化合物
RU2356908C2 (ru) Новые противоопухолевые соединения
KR101149095B1 (ko) 4-메틸헥사노 카할라리드 ｆ 화합물
HK1082261B (en) 4-methylhexanoic kahalalide f compound
UA80992C2 (en) Kahalaide antitumoral compound, use thereof and process for the preparation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091117

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091216

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121225

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121225

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131225

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees